Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates

Pyrazinamide (PZA) is one of the first-line agents used for the treatment of tuberculosis. However, current phenotypic PZA susceptibility testing in the Bactec MGIT 960 system is unreliable, and false resistance is well documented. Rapid identification of resistance-associated mutations can confirm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Mok, Simone, Roycroft, Emma, Flanagan, Peter R., Montgomery, Lorraine, Borroni, Emanuele, Rogers, Thomas R., Fitzgibbon, Margaret M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2021
Soggetti:
Susceptibility
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284449/
https://ncbi.nlm.nih.gov/pubmed/33972244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02617-20
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi